Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer

Opinion
Video

Panelists discuss how, Copper-64 (^64Cu)–labeled PSMA-targeted PET imaging is emerging as a promising modality in prostate cancer diagnosis. The phase 2 SOLAR study (NCT05653856) demonstrated that ^64Cu-PSMA I&T PET/CT effectively detects metastatic prostate cancer, meeting primary end points related to correct localization rates. Compared with gallium-68 (^68Ga) and fluorine-18 (^18F), ^64Cu offers a half-life of approximately 12.7 hours, facilitating centralized production and distribution, which may improve accessibility

Video content above is prompted by the following:

  • Discuss the emerging role of CU-PSMA-targeted PET imaging in prostate cancer.
    • SOLAR phase 2 study – Cu-64-PSMA I&T (NCT05653856)
    • 61Cu-PSMA–targeted PET for prostate cancer (Bernabeu et al. J Nucl Med. 2024)
  • How do copper isotopes compare with others (gallium and fluorine) in terms of half-life, production logistics, image quality, etc?
  • What potential advantages may copper-based isotopes offer over gallium or fluorine isotopes?
  • Where do you see Cu-PSMA–targeted PET fitting in the current treatment landscape, and how might it influence future treatment approaches in prostate cancer?
Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content